These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27321321)

  • 1. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kim YG; Min SH; Hahn S; Oh TJ; Park KS; Cho YM
    Diabetes Res Clin Pract; 2016 Jun; 116():86-95. PubMed ID: 27321321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.
    Yang W; Cai X; Gao X; Chen Y; Chen L; Ji L
    J Diabetes Investig; 2018 Jul; 9(4):813-821. PubMed ID: 29047219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
    Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Stoimenis D; Karagiannis T; Katsoula A; Athanasiadou E; Kazakos K; Bekiari E; Matthews DR; Tsapas A
    Expert Opin Pharmacother; 2017 Jun; 18(9):843-851. PubMed ID: 28448177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
    Tricco AC; Antony J; Khan PA; Ghassemi M; Hamid JS; Ashoor H; Blondal E; Soobiah C; Yu CH; Hutton B; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ Open; 2014 Dec; 4(12):e005752. PubMed ID: 25537781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
    Chen C; Yu Q; Zhang S; Yang P; Wang CY
    Int J Clin Exp Pathol; 2015; 8(11):14141-50. PubMed ID: 26823727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin.
    Shibuki K; Shimada S; Aoyama T
    J Diabetes Res; 2020; 2020():6321826. PubMed ID: 33224988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
    Tran S; Retnakaran R; Zinman B; Kramer CK
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
    Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
    Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
    Park H; Park C; Kim Y; Rascati KL
    Ann Pharmacother; 2012 Nov; 46(11):1453-69. PubMed ID: 23136353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.
    Cho YK; Kim YJ; Kang YM; Lee SE; Park JY; Lee WJ; Jung CH
    J Diabetes Investig; 2018 Jul; 9(4):882-892. PubMed ID: 29215196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.